[1] Estes C, Anstee QM, Teresa AM, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol, 2018, 69:896-904.
[2] Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology, 2016, 64: 1577-1586.
[3] Rinaldi L, Nascimbeni F, Giordano M, et al. Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. World J Gastroenterol, 2017, 23:1458-1468.
[4] Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology, 1999, 29:664-669.
[5] Kim BS, Seo YS, Kim YS, et al. Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis. J Gastroenterol Hepatol, 2018, 33:503-510.
[6] Flemming JA, Kim WR, Brosgart CL, et al. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology, 2017, 65:804-812.
[7] Kabbany MN, Conjeevaram Selvakumar PK, Watt K, et al. Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the united states: an analysis of National Health and Nutrition Examination survey data. Am J Gastroenterol, 2017, 112:581-587.
[8] Setiawan VW, Stram DO, Porcel J, et al. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort. Hepatology, 2016, 64:1969-1977.
[9] 王秀珍,刘雪峰. 2041例肝硬化病因及并发症分析. 浙江医学, 2017, 39:37-39.
[10] Kang JH, Matsui T. Changing etiology in liver cirrhosis in Sapporo, Japan. Euroasian J Hepatogastroenterol, 2018, 8:77-80.
[11] Mohammed OK, Mahadeva S. Clinical outcomes of cryptogenic compared with non-cryptogenic cirrhosis: A retrospective cohort study. J Gastroenterol Hepatol, 2015, 30:1423-1428.
[12] Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrho-sis to hepatocellular carcinoma. Gastroenterology, 2002, 123:134-140.
[13] Lai KK, Shang S, Lohia N, et al. Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models. PLoS Genet, 2011, 7: e1002147.
[14] Calvo F, Ege N, Grande-Garcia A, et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol, 2013, 15:637-646.
[15] Dal Bello B, Rosa L, Campanini N, et al. Glutamine synthetase immunostaining correlates with pathologic features of hepa-tocellular carcinoma and better survival after radiofrequency thermal ablation. Clin Cancer Res, 2010, 16: 2157-2166.
[16] Sohn BH, Park IY, Shin JH, et al. Glutamine synthetase mediates sorafenib sensitivity in β-catenin-active hepatocellular carcinoma cells. Exp Mol Med, 2018, 50:e421.
[17] Ju MJ, Qiu SJ, Fan J, et al. Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. Am J Clin Pathol, 2009, 131: 498-510.
[18] Zhang DY, Goossens N, Guo J, et al. A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. Gut, 2016, 65:1754-1764.
[19] Lau EY, Lo J, Cheng BY, et al. Cancer-associated fibroblasts regulate tumor-initiating cell plasticity in hepatocellular carci-noma through c-Met/FRA1/HEY1 signaling. Cell Rep, 2016, 15: 1175-1189.
[20] Zhao W, Zhang L, Yin Z, et al. Activated hepatic stellate cells promote hepatocellular carcinoma development in immunoco-mpetent mice. Int J Cancer, 2011, 129: 2651-2661.
[21] Alkhouri N, Hanouneh IA, Zein NN, et al. Liver trans-plantation for nonalcoholic steatohepatitis in young patients. Transpl Int, 2016, 29: 418-424.
[22] Golabi P, Bush H, Stepanova M, et al. Liver transplantation (LT) for cryptogenic cirrhosis (CC) and nonalcoholic steato-hepatitis (NASH) cirrhosis: Data from the scientific registry of transplant recipients (SRTR): 1994 to 2016. Medicine (Baltimore), 2018, 97: e11518.
[23] Kelley AS, Deb P, Du Q, et al. Hospice enrollment saves money for Medicare and improves care quality across a number of different lengths-of-stay. Health Aff (Millwood), 2013, 32: 552-561.
[24] Patel AA, Walling AM, Ricks-Oddie J, et al. Palliative care and health care utilization for patients with end-stage liver disease at the end of life. Clin Gastroenterol Hepatol, 2017, 15:1612-1619. |
